The Sidney Kimmel Comprehensive Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Biological: cetuximabProcedure: conventional surgery
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2018-10-24
- Target Recruit Count
- 249
- Registration Number
- NCT00276744
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2010-08-09
- Target Recruit Count
- 46
- Registration Number
- NCT00276588
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Capecitabine in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2020-01-27
- Target Recruit Count
- 26
- Registration Number
- NCT00274768
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸DeCesaris Cancer Institute at Anne Arundel Medical Center, Annapolis, Maryland, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
Modafinil in Opioid Induced Sedation
- Conditions
- PainCancer
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2018-05-07
- Target Recruit Count
- 90
- Registration Number
- NCT00267332
- Locations
- 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
- Conditions
- Graft Versus Host DiseaseLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2014-04-17
- Target Recruit Count
- 72
- Registration Number
- NCT00265837
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia
- Conditions
- Leukemia
Infrared Thermography in Finding Skin Lesions in Patients With Kaposi's Sarcoma
- Conditions
- Sarcoma
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2019-03-20
- Target Recruit Count
- 3
- Registration Number
- NCT00265902
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2019-06-12
- Target Recruit Count
- 97
- Registration Number
- NCT00262730
- Locations
- 🇺🇸
Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham, Alabama, United States
🇺🇸Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- Biological: rituximab
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2017-12-06
- Target Recruit Count
- 21
- Registration Number
- NCT00258206
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
- Conditions
- Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2010-03-17
- Target Recruit Count
- 60
- Registration Number
- NCT00255710
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States